Novel combination of IDO1 inhibitor and immune checkpoint inhibitor proves active in select solid tumors.
In a phase II expansion study, the combination had a low incidence of grade 3/4 adverse events across all tumor types evaluated.
A nearly 3-year follow-up confirmed superiority of pembrolizumab over ipilimumab in patients with advanced melanoma.
First presentation of efficacy data suggests checkpoint inhibitor combination is effective in these patients, with intracranial ORR of 55%.
Combination treatment doubled ORR vs ipilimumab alone with no unexpected toxicity.